Continued Treatment With Nintedanib In Patients With Systemic Sclerosis-Associated Interstitial Lung Disease (Ssc-Ild): Interim Analysis Of Senscis-On

Introduction: In the SENSCIS trial with SSc-ILD, nintedanib (NIN) reduced the rate of decline in FVC (mL/year) over 52 weeks by 44% vs. placebo, with adverse events (AEs) that were manageable for most patients. SENSCIS (NCT02597933) was followed by an open-label extension trial, SENSCIS-ON (NCT03313180), to provide safety data, including data on FVC decline and AEs over the longer term.